C7 Protein
Purified human C7 protein
Product Specifications
| Citations | 5 |
|---|---|
| Description |
Purified human C7 protein |
| Storage | Store at -70°C or below. Avoid freeze/thaw. |
| Form |
Frozen liquid. 10 mM sodium phosphate, 145 mM NaCl, pH 7.3. No preservative, 0.22 µm filtered. |
| Concentration | 1.0 mg/mL (refer to CoA for lot specific concentration) |
| Applications |
See citations and technical data sheet for application info. |
Ordering Information
| Catalog Number | A405 |
|---|---|
| Catalog Number (CE) | N/A |
| Size | 250 µL |
| Price (USD) | $305.00 |
| Price (EURO) | 275,00 € |
Contact us
| US Phone | +1 (858) 552 1100 |
|---|---|
| EU Phone | +353 (91) 412 474 |
| US Email | contact-us@quidelortho.com |
| EU Email | contact-emea@quidelortho.com |
- Specifications
- Citations
- Certificate of Analysis
Specifications
| Description |
Purified human C7 protein |
|---|---|
| Size | 250 µL |
| Storage |
Store at -70°C or below. Avoid freeze/thaw. |
| Form | Frozen liquid. 10 mM sodium phosphate, 145 mM NaCl, pH 7.3. No preservative, 0.22 µm filtered. |
| Concentration | 1.0 mg/mL (refer to CoA for lot specific concentration) |
| Applications | See citations and technical data sheet for application info. |
| Purity | >90% by SDS-PAGE |
| Source |
Normal human serum |
| Activity | >95% versus normal human serum standard |
| Molecular Weight | 92,400 Da (single chain) |
| Background |
Purified human complement component C7. Complement component C7 is unique to the terminal complement pathway. It is a single chain protein with a molecular weight of 110 kD and is present in plasma at approximately 55 mg/L. Together with the other proteins of the terminal pathway, C7 forms the membrane attack complex or MAC. |
Citations
| Title | Year | Applications | Sample Species | Sample | Sample Details |
|---|---|---|---|---|---|
| 2012 | TER Measurements |
Cell Culture |
RPE Cells |
||
| 2012 | Bacterial plating |
Human |
Serum |
C7 Depleted |
|
|
Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury |
2009 | TER Measurements |
Human |
ARPE-19 Cells |
|
|
Persistent complement dysregulation with signs of thromboinflammation in active Long Covid |
2024 | ELISA |
Human |
Serum |
COVID-19 |